Skip to content

Study · In silico · 2026

6 results

A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.

Rahman E, Webb WR, Carruthers JDA

Aesthetic plastic surgery17 Jun 2026

PMID42310090 (opens in a new tab)DOI10.1007/s00266-026-05973-2 (opens in a new tab)PepBankPUB-42310090
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01Computer modelIn silicoEfficacy outcome

    In a simulated cohort of digital twins with BMI above 30, 3-month semaglutide pre-treatment before Sofwave gave the greatest net benefit, +0.092 in cycling fibroblast AUC.

    In plain wordsIn a computer simulation, starting semaglutide 3 months before ultrasound skin tightening gave the best predicted fibroblast activity. This is not human data.

    Peptide
    Semaglutide
    Outcome
    IncreaseTime-integrated cycling fibroblast burden (AUC) with 3-month semaglutide pre-treatment
    Study

    n: not reported in source

    Virtual randomized trial of 20,000 digital twins (finite element plus agent-based model)
    Analysis
    Primary
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 3 months pre-treatmentAs given in this study.

    Measurements

    Cycling AUC change
    0.092 AUC
    3-month pre-treatment

    Source sentences

    Summary
    Semaglutide timing created a non-monotonic effect: 3-month pre-treatment yielded the greatest net benefit (+0.092 cycling AUC, +41% collagen density).
    3 context sentences
    Summary · context
    The primary endpoint was the time-integrated cycling fibroblast burden (AUC).
    Summary · context
    We conducted a first fully computational, mechanistically constrained virtual randomized trial.
    Summary · context
    A cohort of 20,000 digital twins (BMI >30 kg/m2) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only).
  2. 02Computer modelIn silicoEfficacy outcome

    In the simulation, 3-month semaglutide pre-treatment before Sofwave increased collagen density by 41%.

    In plain wordsIn a computer simulation, starting semaglutide 3 months before ultrasound skin tightening predicted 41% more collagen. This is not human data.

    Peptide
    Semaglutide
    Outcome
    IncreaseCollagen density with 3-month semaglutide pre-treatment
    Study

    n: not reported in source

    Virtual randomized trial of 20,000 digital twins (finite element plus agent-based model)
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 3 months pre-treatmentAs given in this study.

    Measurements

    Collagen density change
    41%
    3-month pre-treatment

    Source sentences

    Summary
    Semaglutide timing created a non-monotonic effect: 3-month pre-treatment yielded the greatest net benefit (+0.092 cycling AUC, +41% collagen density).
    2 context sentences
    Summary · context
    We conducted a first fully computational, mechanistically constrained virtual randomized trial.
    Summary · context
    A cohort of 20,000 digital twins (BMI >30 kg/m2) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only).
  3. 03Computer modelIn silicoMechanism

    In the simulation, direct fibroblast priming by semaglutide added +0.118 to cycling AUC.

    In plain wordsIn a computer simulation, semaglutide acted directly on skin fibroblasts and raised their predicted activity. This is not human data.

    Peptide
    Semaglutide
    Outcome
    IncreaseDirect fibroblast priming by semaglutide
    Study

    n: not reported in source

    Virtual randomized trial of 20,000 digital twins (finite element plus agent-based model)
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Direct priming AUC
    0.118 AUC
    simulation

    Source sentences

    Summary
    This benefit resulted from balancing direct fibroblast priming (+0.118 AUC) against indirect adipose support loss (-0.026 AUC).
    2 context sentences
    Summary · context
    We conducted a first fully computational, mechanistically constrained virtual randomized trial.
    Summary · context
    A cohort of 20,000 digital twins (BMI >30 kg/m2) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only).
  4. 04Computer modelIn silicoMechanism

    In the simulation, indirect loss of adipose support with semaglutide lowered cycling AUC by 0.026.

    In plain wordsIn a computer simulation, semaglutide-related fat loss reduced the support for skin fibroblasts, which lowered predicted activity. This is not human data.

    Peptide
    Semaglutide
    Outcome
    DecreaseIndirect adipose support loss with semaglutide
    Study

    n: not reported in source

    Virtual randomized trial of 20,000 digital twins (finite element plus agent-based model)
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Indirect adipose support loss AUC
    −0.026 AUC
    simulation

    Source sentences

    Summary
    This benefit resulted from balancing direct fibroblast priming (+0.118 AUC) against indirect adipose support loss (-0.026 AUC).
    2 context sentences
    Summary · context
    We conducted a first fully computational, mechanistically constrained virtual randomized trial.
    Summary · context
    A cohort of 20,000 digital twins (BMI >30 kg/m2) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only).
  5. 05Computer modelIn silicoEfficacy outcome

    In the simulation, prolonged 6-month semaglutide pre-treatment was detrimental in high insulin resistance phenotypes (90th percentile delta AUC -0.006).

    In plain wordsIn a computer simulation, 6 months of semaglutide before skin tightening predicted worse results for high insulin resistance. Not human data.

    Peptide
    Semaglutide
    Outcome
    DecreaseCycling AUC with 6-month semaglutide pre-treatment in high insulin resistance phenotypes
    Study

    n: not reported in source

    Virtual randomized trial of 20,000 digital twins (finite element plus agent-based model)
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 6 months pre-treatmentAs given in this study.

    Measurements

    90th percentile delta AUC
    −0.006 AUC
    6-month pre-treatment, high IR

    Source sentences

    Summary
    Prolonged (6-month) pre-treatment was detrimental in high-IR phenotypes (90th percentile ΔAUC: -0.006).
    2 context sentences
    Summary · context
    We conducted a first fully computational, mechanistically constrained virtual randomized trial.
    Summary · context
    A cohort of 20,000 digital twins (BMI >30 kg/m2) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only).
  6. 06Computer modelIn silicoEfficacy outcome

    In the simulation, the 3-month semaglutide pre-treatment arm produced a more isotropic extracellular matrix, with an anisotropy index of 0.26 versus 0.41 in control.

    In plain wordsIn a computer simulation, 3 months of semaglutide before skin tightening predicted a more evenly arranged skin matrix than control. This is not human data.

    Peptide
    Semaglutide
    Outcome
    DecreaseECM anisotropy index with 3-month semaglutide pre-treatment
    Study

    n: not reported in source

    Virtual randomized trial of 20,000 digital twins (finite element plus agent-based model)
    Comparator
    Control (Sofwave only)
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 3 months pre-treatmentAs given in this study.

    Measurements

    Anisotropy index
    0.26
    3-month pre-treatment
    Anisotropy index
    0.41
    control

    Source sentences

    Summary
    The 3-month pre-treatment arm also produced a more isotropic ECM (anisotropy index: 0.26 vs. 0.41 in control).
    2 context sentences
    Summary · context
    We conducted a first fully computational, mechanistically constrained virtual randomized trial.
    Summary · context
    A cohort of 20,000 digital twins (BMI >30 kg/m2) was randomized across five arms receiving identical Sofwave schedules, but varying semaglutide start times (concurrent, 1, 3, or 6 months pre-treatment, vs. Sofwave-only).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.